ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Hop Oil: A Safe Sleep Aide

Lutein — An Important Nutrient for Eye and Brain Health

White Camphor Oil: The Purest Camphor Oil

Taurine: Facts About This Crucial Amino Acid

 
Print Page
Email Article

What Do We Know About Diagnosing AD?

  [ Not Yet Rated ]   [ Discuss This Article ]
By 1999 Progress Report by the NIA/NIH • www.ProHealth.com • December 13, 1999


Currently, clinicians use several tools to diagnose "possible AD" or "probable AD" in a patient who is having difficulties with memory or other mental functions. These tools include a patient history, physical exam, laboratory tests, brain scans, and a series of tests that measure memory, language skills, and other abilities related to brain functioning. However, in these patients, AD can be diagnosed conclusively only by examining the brain after death in an autopsy to determine the presence of characteristic plaques and tangles in certain brain regions.

The earlier an accurate diagnosis of AD is made, the greater the gain in managing symptoms and determining the natural history of AD. An early, accurate diagnosis of AD is especially important to patients and their families because it helps them plan for the future and pursue care options while the patient can still take part in making decisions.

Researchers have made significant progress in developing accurate diagnostic tests and techniques that can be used in living patients. In specialized research facilities, clinicians can now diagnose AD with up to 90 percent accuracy. For example, work is underway to develop new tests of mental status that might be used to distinguish between people who might have very early AD symptoms and those experiencing age-related normal memory loss. Other investigators have explored the utility of analyzing cerebrospinal fluid for levels of "sticky" beta-amyloid and tau for diagnosing AD. Researchers also have used positron emission tomography (PET) scans, an imaging method in living patients, to see whether they can detect changes in the way glucose is metabolized in parts of the brain that are most affected by AD. Another imaging method, known as single photon emission computed tomography (SPECT), also has been combined with genetic and psychological testing to predict which people with memory problems eventually will develop clinically diagnosed AD.

A particularly exciting area of work involves yet another imaging technique in the diagnosis of AD. This technique uses magnetic resonance imaging (MRI) to measure the size of various structures in the brain. Many studies have shown that AD causes some brain structures, particularly the hippocampus, to shrink early on in the disease, and scientists are exploring exactly how early this shrinkage, or atrophy, can be detected. Several teams of NIA-funded scientists have established the usefulness of MRI as a tool to help determine which people with memory problems are in the earliest stages of AD; to identify people who will later be diagnosed with AD; and to measure hippocampal volume to distinguish between people with mild cognitive impairment (MCI) and those with no memory or learning problems, and between people without AD and those with very mild AD.

Source:
National Institutes of Health
National Institute on Aging
1999 PROGRESS REPORT ON ALZHEIMER'S DISEASE



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Vitamin D3 Extreme™ FibroSleep™


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root
"It's Not Easy Being Green" - But It Is Healthy
A Hard-Working Molecule that May Help Ease Pain & Brighten Mood A Hard-Working Molecule that May Help Ease Pain & Brighten Mood
Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery
Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map